The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...

"Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Catalent’s acquisition by Novo Holdings, to help Novo Nordisk meet manufacturing demand for glucagon-like peptide (GLP)-1 obesity medicines, has taken sterile fill-finish capacity out of the market, ...

The start-up expects to advance its lead asset—a once-weekly oral glucagon-like peptide 1 (GLP-1) receptor agonist—into Phase 2 trials for weight loss and the treatment of obesity later this year.

About Oral Ecnoglutide (XW004): Glucagon-like peptide-1 (GLP-1 ... (NDA stage), oral GLP-1 peptide Ecnoglutide tablet XW004 (Phase I), and oral small molecule GLP-1 receptor agonist XW014 (Phase I).

This includes a Phase II-ready oral glucagon-like peptide-1 receptor agonist (GLP-1RA) ecnoglutide, a potential first-in-class oral amylin agonist, and a long-acting subcutaneous amylin agonist. These ...